Max Healthcare, leading healthcare providers of North India, along with Imperial College, London and European Commission on July 20 officially announced the launch of a 3-year iHealth Type 2 Diabetes study.
Overview
- Led by Professor John Chambers and Professor Jaspal Singh Kooner from Imperial College of London, UK and includes experts from India, Pakistan and Sri Lanka.
- Dr Sujeet Jha (Director,Institute of Endocrinology, Diabetes and Metabolism – Max Healthcare) is the lead for India, building on his established international collaborative epidemiological efforts to understand the genetic and environmental factors influencing type 2 diabetes (T2D) in South Asians.
- Will be using much simpler tools than what has been used so far
Other Details
- The study in India has commenced this month (July), 2016 and will conclude in July, 2019
The study will analyse and determine whether:
- Family-based lifestyle modification v/s usual care reduces risk of T2D (primary endpoint) among South Asians with:
- Central obesity
- Prediabetes
- Overall (with central obesity and / or obesity)
- Compare effectiveness of the interventions between groups
- Health economic analysis of family-based lifestyle modification v/s usual care for prevention of T2D on the Indian subcontinent and Europe
- Quantify the cost-effectiveness of screening by waist circumference v/s HbA1c
iHealth Type2 DiabetesStudy “ Key Takeaways
- Will map 10,000 citizens of India with pre-diabetic symptoms
- Will focus on health promotion & prevention of T2D among South Asians
- Will involve both men & women from the Indian subcontinent (India, Pakistan and Sri Lanka), as well as the United Kingdom to provide evidence about the implementation of lifestyle modification in both high- and low-income settings
- Will address the limitations of current approaches towards diabetes management
- Will be an expansive study of South Asians in diverse settings
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.